

Press Release: Cardio Control NV,  
August 21, 2002

**Cardio Control: Profitable In 2nd Quarter  
- Revenue Up By 57%, Net Profit 9% of Revenue -**

Key figures (x €1.000)	first 6 months		% change
	2002	2001	
Sales	3,661	2,732	+34%
COGS	1,048	1,113	- 6%
Expenses	2,613	2,027	+26%
Operating Result	52	- 408	N.A.
Net Result	-241	- 334	+60%
Profit per share in eurocents	- 8	- 11	+60%
Group Equity	5,024	5,303	- 5%
Balance Sheet Total	6,741	7,458	- 10%
Solvability	75%	71%	+ 6%
Gross margin	71%	69%	+ 3%

**Cardio Control NV, specializing in medical diagnostic software and systems and listed at Euro.NM of the Euronext Stock Exchange in Amsterdam, closed their second quarter with an increase in Revenue of 57% and a Net Result of €19,000. This is a significant increase compared to a negative €108,000 in the same quarter last year and compared to this year's first quarter, when a Net Loss of €460,000 was reported. Comparatively, the company's total revenue amounted to €2.4 million to the former €1.5 million within the same period of 2001 and just over €1,2 million in the first quarter of this year.**

The Gross Result of the first six months was €52,000. This amount reflects a dramatic change compared to the former year's negative €408,000. Revenue during this period resulted in €3.7 Mil compared to the €2.7 Mil in 2001; (an increase of 34%). Due to two extraordinary factors, the depreciation of the dollar as well as a paper loss on the a minority participation in Nasdaq-listed Angeion Corporation from Minneapolis, the net result of the first six months was a negative €241,000; (i.e., 2001: negative €334,000). The seasonal pattern that strongly influences Cardio Control's spread of revenue, normally does not lead to profits in the first part of the year. Over the company's last ten years, approximately two thirds

of their annual revenue had been realized in the second part of the year.

With positive expectations for the second half of 2002, Cardio Control seems to be on its way to close the year with a solid result. In a comment, Mr. Dick van Luijk, CEO, was quoted saying: *“The deliveries and installations of the farmaceutical mega-order we reported just before the summer are on schedule. Most of the installations take place within the third quarter. Our last quarter is historically our best one, giving us a lot of confidence in the year-end results.”*

No details of upcoming statements are being released due to uncertain economic conditions. In general, Cardio Control expects this significant growth trend to continue over the next few years.

For additional information about Cardio Control and its products, reference its website at: [www.cardiocontrol.com](http://www.cardiocontrol.com). A Webcast presentation related to these figures with Cardio Control's CEO Dick G. van Luijk is also available on this website.

For questions regarding this press release:  
Investor Relations Department  
Cardio Control NV  
Mercuriusweg 1  
2624 BC Delft  
Netherlands  
[info@cardiocontrol.com](mailto:info@cardiocontrol.com)  
Tel: (+31) 15-750.5000 Fax: (+31) 15-750.5055